Overview Dividends

(SNN) Smith & Nephew SNATS - Ratings and Ratios

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US83175M2052

Orthopaedics, Sports Medicine, Wound Care, Implants, Biologics

Health Care Equipment
Market Cap in USD: 13,955m

IPO / Inception: 1999-11-16
Return 12m vs S&P 500: 18.4%

EPS (Earnings per Share)

EPS CAGR: -73.48%
EPS Trend: 4.5%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 24.86%
Rev. Trend: 39.8%

Qual. Beats: 0

Dividends

Dividend Yield	2.26%
Yield on Cost 5y	2.01%
Yield CAGR 5y	0.40%
Payout Consistency	95.5%
Payout Ratio	136.1%

Risk via 5d forecast
Volatility	25.7%
Value at Risk 5%th	38.1%
Relative Tail Risk	-9.98%

Reward TTM
Sharpe Ratio	1.14
Alpha	30.63
CAGR/Max DD	0.26

Character TTM
Hurst Exponent	0.340
Beta	0.484
Beta Downside	0.625

Drawdowns 3y
Max DD	33.29%
Mean DD	11.55%
Median DD	10.71%

Description: SNN Smith & Nephew SNATS January 03, 2026

Smith & Nephew plc (NYSE:SNN) designs, manufactures and markets a broad portfolio of medical-device products across three operating segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The firm serves hospitals and other healthcare providers in the U.K., the United States and globally.

Its Orthopaedics line includes knee and hip implants (including revision-type hip devices), trauma and extremities fixation systems, and other reconstruction solutions. The Sports Medicine & ENT segment supplies minimally invasive joint-repair instruments, arthroscopic visualization equipment, and ENT devices. Advanced Wound Management offers chronic-wound dressings, biologic grafts, negative-pressure therapy (both reusable and single-use), and hydrosurgery platforms.

Key recent metrics: FY 2023 revenue reached approximately **$5.2 billion**, up 7 % YoY, driven primarily by a **10 % growth rate in orthopaedic sales** and a **6 % rise in wound-care revenue**. R&D spending remained steady at **~7 % of sales**, supporting pipeline launches such as a next-generation knee implant that received FDA clearance in Q3 2024. The United States now accounts for roughly **55 % of total revenue**, reflecting the market’s reliance on high-volume joint-replacement procedures.

Sector-level drivers that shape Smith & Nephew’s outlook include an aging global population (projected to add ~30 million new joint-replacement candidates in the next decade), tightening reimbursement policies that favor cost-effective, minimally invasive solutions, and ongoing supply-chain pressures that have heightened the value of single-use, sterilization-free devices. These macro trends underpin the company’s focus on high-margin, technology-enabled product lines.

For a deeper, data-driven assessment of SNN’s valuation and risk profile, you may find the analytical tools on **ValueRay** worth exploring.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (814.6m TTM) > 0 and > 6% of Revenue (6% = 612.7m TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA 5.42pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 30.20% (prev 21.13%; Δ 9.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.14 (>3.0%) and CFO 1.51b > Net Income 814.6m (YES >=105%, WARN >=100%)

Net Debt (2.78b) to EBITDA (2.22b) ratio: 1.25 <= 3.0 (WARN <= 3.5)

Current Ratio 3.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (439.9m) change vs 12m ago -49.60% (target <= -2.0% for YES)

Gross Margin 69.95% (prev 70.14%; Δ -0.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 98.80% (prev 83.34%; Δ 15.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.98 (EBITDA TTM 2.22b / Interest Expense TTM 254.8m) >= 6 (WARN >= 3)

Altman Z'' 5.29

(A) 0.29 = (Total Current Assets 4.62b - Total Current Liabilities 1.54b) / Total Assets 10.68b

(B) 0.48 = Retained Earnings (Balance) 5.12b / Total Assets 10.68b

(D) 0.96 = Book Value of Equity 4.96b / Total Liabilities 5.15b

Total Rating: 5.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 71.68

1. Piotroski 7.0pt

2. FCF Yield 5.37%

3. FCF Margin 8.80%

4. Debt/Equity 0.62

5. Debt/Ebitda 1.25

6. ROIC - WACC (= 5.29)%

7. RoE 15.37%

8. Rev. Trend 39.77%

9. EPS Trend 4.50%

What is the price of SNN shares?

As of January 08, 2026, the stock is trading at USD 33.70 with a total of 574,780 shares traded.
Over the past week, the price has changed by +2.71%, over one month by +0.63%, over three months by -5.68% and over the past year by +40.36%.

Is SNN a buy, sell or hold?

Smith & Nephew SNATS has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold SNN.

Strong Buy: 1
Buy: 1
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SNN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	36.6	8.7%
Analysts Target Price	36.6	8.7%
ValueRay Target Price	36.2	7.4%

SNN Fundamental Data Overview January 04, 2026

Market Cap USD = 13.95b (13.95b USD * 1.0 USD.USD)
P/E Trailing = 29.6216
P/E Forward = 12.1803
P/S = 2.3477
P/B = 2.5153
P/EG = 0.6417
Beta = 0.656
Revenue TTM = 10.21b USD
EBIT TTM = 1.27b USD
EBITDA TTM = 2.22b USD
Long Term Debt = 3.15b USD (from longTermDebt, last quarter)
Short Term Debt = 156.9m USD (from shortTermDebt, last quarter)
Debt = 3.45b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.78b USD (from netDebt column, last quarter)
Enterprise Value = 16.73b USD (13.95b + Debt 3.45b - CCE 675.4m)
Interest Coverage Ratio = 4.98 (Ebit TTM 1.27b / Interest Expense TTM 254.8m)
FCF Yield = 5.37% (FCF TTM 898.3m / Enterprise Value 16.73b)
FCF Margin = 8.80% (FCF TTM 898.3m / Revenue TTM 10.21b)
Net Margin = 7.98% (Net Income TTM 814.6m / Revenue TTM 10.21b)
Gross Margin = 69.95% ((Revenue TTM 10.21b - Cost of Revenue TTM 3.07b) / Revenue TTM)
Gross Margin QoQ = 70.62% (prev 69.46%)
Tobins Q-Ratio = 1.57 (Enterprise Value 16.73b / Total Assets 10.68b)
Interest Expense / Debt = 2.37% (Interest Expense 81.7m / Debt 3.45b)
Taxrate = 19.06% (69.6m / 365.3m)
NOPAT = 1.03b (EBIT 1.27b * (1 - 19.06%))
Current Ratio = 3.00 (Total Current Assets 4.62b / Total Current Liabilities 1.54b)
Debt / Equity = 0.62 (Debt 3.45b / totalStockholderEquity, last quarter 5.53b)
Debt / EBITDA = 1.25 (Net Debt 2.78b / EBITDA 2.22b)
Debt / FCF = 3.09 (Net Debt 2.78b / FCF TTM 898.3m)
Total Stockholder Equity = 5.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.63% (Net Income 814.6m / Total Assets 10.68b)
RoE = 15.37% (Net Income TTM 814.6m / Total Stockholder Equity 5.30b)
RoCE = 15.01% (EBIT 1.27b / Capital Employed (Equity 5.30b + L.T.Debt 3.15b))
RoIC = 11.92% (NOPAT 1.03b / Invested Capital 8.62b)
WACC = 6.63% (E(13.95b)/V(17.41b) * Re(7.80%) + D(3.45b)/V(17.41b) * Rd(2.37%) * (1-Tc(0.19)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 81.65 | Cagr: 0.11%
[DCF Debug] Terminal Value 79.26% ; FCFE base≈658.4m ; Y1≈705.3m ; Y5≈858.7m
Fair Price DCF = 35.35 (DCF Value 15.00b / Shares Outstanding 424.4m; 5y FCF grow 7.97% → 3.0% )
EPS Correlation: 4.50 | EPS CAGR: -73.48% | SUE: 0.0 | # QB: 0
Revenue Correlation: 39.77 | Revenue CAGR: 24.86% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=1.80 | Chg30d=+0.006 | Revisions Net=-2 | Growth EPS=+11.7% | Growth Revenue=+5.3%

Additional Sources for SNN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle